– Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company’s …

SAN FRANCISCO, June 16, 2016 (GLOBE NEWSWIRE) — Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia in Colombia, to further evaluate the company’s DJ-1 protein-targeting small molecule pharmaceutical chaperone drug candidates in development for the treatment of Parkinson’s disease (PD). The partnership brings together Cantabio’s novel approach and the University of Antioquia’s research excellence on the role of oxidative stress in PD and other neurodegenerative diseases.Pharmaceutical chaperones are small molecules that are designed to enter cells and serve as molecular scaffolding to prevent or reverse the misfolding and the loss of function of proteins. Misfolded proteins are associated with numerous diseases particularly neurodegenerative diseases including PD and Alzheimer’s disease.Research from the ongoing collaboration is elucidating the precise cellular signaling mechanism…


Link to Full Article: – Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company’s …